mirvetuximab
immunogen
['ovarian', 'biomarker', 'mirasol']
 the results from the mirasol study which looks at the antibody-drug conjugate mirvetixumab for folri- positive platinum resistant ovarian cancer (folri is a biomarker that is tested on your tumor) and this drug improves survival compared to chemotherapy. #asco23 
MD @harvard ,MSc medical Oncology, #breastcancer & Researcher American Board Certified.Member of the European Society of Oncology. 𝒞ℴ𝒻𝒻ℯℯ ☕︎♥︎